Biogen Inc. Common Stock
Symbol: BIIB (NASDAQ)
143.70
▲ (0.07%) 0.099
Company Description:
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Key Stats
- Today's Open: $143
- Today's High: $144
- Today's Low: $139.72
- Today's Volume: 1.28M
- Yesterday Close: $143.6
- Yesterday High: $143.74
- Yesterday Low: $140.51
- Yesterday Volume: 1.49M
- Last Min Volume: 0
- Last Min High: $143.699
- Last Min Low: $143.699
- Last Min VWAP: $0
Company Profile
- Name: Biogen Inc. Common Stock
- Website: https://www.biogen.com
- Listed Date: 1991-09-17
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0000875045
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $20.72B
- Round Lot: 100
- Outstanding Shares: 146.61M
- Asset Type: CS
RECENT FILINGS FOR BIIB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-02 | 4 | View |
| 2025-09-02 | 144 | View |
| 2025-07-31 | 8-K | View |
| 2025-07-31 | 10-Q | View |
| 2025-07-30 | SCHEDULE 13D/A | View |
| 2025-07-21 | SCHEDULE 13D/A | View |
| 2025-07-16 | 4 | View |
| 2025-07-08 | 144 | View |
| 2025-07-07 | 8-K | View |
| 2025-06-23 | 8-K | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
Latest News on BIIB